Zentalis Pharmaceuticals Llc - Asset Resilience Ratio
Zentalis Pharmaceuticals Llc (ZNTL) has an Asset Resilience Ratio of 72.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Zentalis Pharmaceuticals Llc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Zentalis Pharmaceuticals Llc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Zentalis Pharmaceuticals Llc.
Liquid Assets Composition Over Time
This chart breaks down Zentalis Pharmaceuticals Llc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Zentalis Pharmaceuticals Llc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $209.90 Million | 72.64% |
| Total Liquid Assets | $209.90 Million | 72.64% |
Asset Resilience Insights
- Very High Liquidity: Zentalis Pharmaceuticals Llc maintains exceptional liquid asset reserves at 72.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zentalis Pharmaceuticals Llc Industry Peers by Asset Resilience Ratio
Compare Zentalis Pharmaceuticals Llc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA |
Biotechnology | 64.92% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 78.22% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Zentalis Pharmaceuticals Llc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Zentalis Pharmaceuticals Llc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 72.64% | $209.90 Million | $288.97 Million | -5.72pp |
| 2024-12-31 | 78.35% | $337.18 Million | $430.34 Million | -2.58pp |
| 2023-12-31 | 80.94% | $454.88 Million | $562.03 Million | +9.69pp |
| 2022-12-31 | 71.24% | $394.30 Million | $553.46 Million | +11.89pp |
| 2021-12-31 | 59.36% | $280.17 Million | $472.02 Million | -18.21pp |
| 2020-12-31 | 77.57% | $283.55 Million | $365.56 Million | -- |
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more